Acute myeloid leukemia

Novel Antibody Therapies Market, 2035 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022

The "Novel Antibody Therapies Market: Distribution by Type of Novel Antibody, Target Indication, Type of Therapy, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Novel Antibody Therapies Market: Distribution by Type of Novel Antibody, Target Indication, Type of Therapy, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • The 'Novel Antibody Therapies Market, 2022-2035' report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the novel antibody therapies in the treatment of various diseases.
  • What are the different initiatives undertaken by big pharma players for the development of novel antibody therapies in the recent past?
  • How is the current and future market opportunity, related to novel antibody therapies likely to be distributed across key market segments?

Kura Oncology to Host Investor Event on December 10, 2022

Retrieved on: 
Thursday, December 1, 2022

The in-person investor event and live webcast will take place on Saturday, December 10, 2022, at 11:15 a.m. CT / 12:15 p.m.

Key Points: 
  • The in-person investor event and live webcast will take place on Saturday, December 10, 2022, at 11:15 a.m. CT / 12:15 p.m.
  • ET, following an oral presentation of updated data from the KOMET-001 trial at the American Society of Hematology (ASH) Annual Meeting in New Orleans.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
  • Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Companys next-generation FTI, through IND-enabling studies.

COTA, Inc. Announces Seven Upcoming Poster Presentations at the 2022 American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, December 1, 2022

NEW YORK, Dec. 1, 2022 /PRNewswire/ -- COTA, Inc. ,an oncology real-world data and analytics company, announced that seven abstracts leveraging COTA's oncology real-world data (RWD) will be presented at the 64th American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, Louisiana, from December 1013, 2022.

Key Points: 
  • NEW YORK, Dec. 1, 2022 /PRNewswire/ -- COTA, Inc. ,an oncology real-world data and analytics company, announced that seven abstracts leveraging COTA's oncology real-world data (RWD) will be presented at the 64th American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, Louisiana, from December 1013, 2022.
  • "There is a continuous need to better understand how emerging therapies are impacting patients in everyday healthcare settings," said C.K.
  • COTA co-authored three of the seven abstracts accepted for poster presentation at the ASH conference.
  • The accepted poster presentations leveraging COTA's oncology real-world data include:

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Retrieved on: 
Wednesday, November 30, 2022

The Phase 1 open-label study is being conducted at the University of Miami, led by Terrence J. Bradley, M.D.

Key Points: 
  • The Phase 1 open-label study is being conducted at the University of Miami, led by Terrence J. Bradley, M.D.
  • We are very pleased that such an experienced team as that at the University of Miami has initiated this trial.
  • In ongoing Phase 2 studies, bomedemstat has been generally well-tolerated and has demonstrated significant symptom improvement for patients with myelofibrosis and essential thrombocythemia .
  • Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185).

BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

Retrieved on: 
Wednesday, November 30, 2022

The global collaboration will consist of two parts: BioNTech will receive a global, exclusive license to develop and commercialize Ryvus STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations.

Key Points: 
  • The global collaboration will consist of two parts: BioNTech will receive a global, exclusive license to develop and commercialize Ryvus STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations.
  • BioNTech has the option to license global development and commercialization rights to these programs at the development candidate stage.
  • The collaboration with Ryvu provides us with the opportunity to complement our immunotherapy pipeline with a portfolio of potent immunomodulatory molecules.
  • BioNTech will fund all discovery, research and development activities, including Ryvus discovery and research activities under the multi-target research collaboration.

MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference

Retrieved on: 
Tuesday, November 29, 2022

MaaT013 is a standardized, high-richness, high-diversity Microbiome Ecosystem TherapyTM containing ButycoreTM (group of bacterial genera known to produce immuno-regulatory metabolites).

Key Points: 
  • MaaT013 is a standardized, high-richness, high-diversity Microbiome Ecosystem TherapyTM containing ButycoreTM (group of bacterial genera known to produce immuno-regulatory metabolites).
  • MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology.
  • MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.
  • MaaT Pharma is the first company developing microbiome-based therapies listed on Euronext Paris (ticker: MAAT).

Pacylex Granted FDA Fast Track Designation for PCLX-001 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Retrieved on: 
Tuesday, November 22, 2022

Edmonton, Alberta--(Newsfile Corp. - November 22, 2022) - Pacylex, a clinical-stage N-myristoyltransferase (NMT) inhibitor company developing first-in-class therapies for leukemia, lymphoma, and solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted PCLX-001 Fast Track Designation for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML).

Key Points: 
  • Edmonton, Alberta--(Newsfile Corp. - November 22, 2022) - Pacylex, a clinical-stage N-myristoyltransferase (NMT) inhibitor company developing first-in-class therapies for leukemia, lymphoma, and solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted PCLX-001 Fast Track Designation for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML).
  • PCLX-001 is a first-in-class N-myristoyltransferase inhibitor which inhibits signaling necessary for cancer cell proliferation and survival in leukemia and lymphoma.
  • PCLX-001 is currently in clinical studies at 4 hospitals in Canada in non-Hodgkin Lymphoma and solid tumor patients.
  • Pacylex is developing PCLX-001 in the form of a once-a-day pill initially to treat leukemia and lymphoma.

Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting

Retrieved on: 
Wednesday, November 23, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit technology platform, will host an Investor Event on December 11 during the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA.

Key Points: 
  • The Investor event will take place in-person and virtually and a webcast of the event will be available on Sentis Events & Presentations page.
  • This meeting is not an official program of the ASH annual meeting.
  • Senti Bio anticipates that subsequent events and developments may cause Senti Bios assessments to change.
  • Availability of Other Information About Senti Biosciences, Inc.
    For more information, please visit the Senti Bio website at https://www.sentibio.com or follow Senti Bio on Twitter (@SentiBio) and LinkedIn (Senti Biosciences).

Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 23, 2022

KRAKOW, Poland, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE:RVU), a clinical-stage drug discovery anddevelopment company focusing on novel small molecule therapies that address emerging targets inoncology, today announced third quarter 2022 financial results and provided a corporate update.

Key Points: 
  • KRAKOW, Poland, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE:RVU), a clinical-stage drug discovery anddevelopment company focusing on novel small molecule therapies that address emerging targets inoncology, today announced third quarter 2022 financial results and provided a corporate update.
  • Cash Position On November 17, 2022, Ryvu Therapeutics held $6.9M in cash, cash equivalents, and short-term investments, compared to $20.5M at the end of 2021.
  • Ryvu Therapeutics is a clinical-stage drug discovery, and development company focused on novel small-molecule therapies that address emerging targets in oncology.
  • Ryvu Therapeutics has signed multiple partnering and licensing deals with global companies, including Merck, Menarini Group, Galapagos andExelixis.

Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split

Retrieved on: 
Tuesday, November 22, 2022

CARLSBAD, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that its board of directors (the “Board”) has approved a 1-for-10 reverse stock split of the Company’s common stock. The reverse stock split will become effective at 12:01 am ET on November 23, 2022 and begin trading on a split-adjusted basis at the market open on November 23, 2022 with the new CUSIP number 74754R 202.

Key Points: 
  • The Company is implementing the reverse stock split to enable it to regain compliance with the Nasdaq $1.00 minimum bid price requirement.
  • As a result of the reverse stock split, every 10 shares of the Companys common stock issued and outstanding will be automatically reclassified into one share of common stock.
  • The reverse stock split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage of Company shares, with the exception of those stockholders receiving cash in lieu of fractional shares.
  • Equiniti Trust Company (Equiniti) is acting as the exchange agent and transfer agent for the reverse stock split.